

Please type a plus (+) inside this box



17236 U.S. PTO



09/16/03

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	6750-244-999	Total Pages	80
First Named Inventor or Application Identifier			
Benjamin Oshlack			
Express Mail Label No.	EV 335856750 US		

**APPLICATION ELEMENTS**


See MPEP chapters 600 concerning utility patent application contents.

Address to:

**Commissioner for Patents  
P.O. Box 1450  
Mail Stop PATENT APPLICATION  
Alexandria, VA 22313-1450**

1. ☒ Fee Transmittal Form [Total Pages 2]  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims Small Entity status, see 37 C.F.R. § 1.27
3. ☒ Specification [Total Pages 53]  
(preferred arrangement set forth below, MPEP 1503.01)
- Descriptive title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description of the Invention (including drawings, if filed)
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 USC 113) (Figs. 1-17) [Total Sheets 17]
5. ☒ Oath or Declaration (Unexecuted) [Total Sheets 2]
- a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)
  - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Form (CRF)
  - b. ☐ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ paper
  - c. ☐ Statement verifying identity of above copies



**ACCOMPANYING APPLICATION PARTS**

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(i). Applicant must attach form PTO/SB/35 or its equivalent
17. ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 09/777,616 filed February 6, 2001.

Prior application information: Examiner: James M. Spear Group Art Unit: 1615

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**19. CORRESPONDENCE ADDRESS**

☒ Customer Number

20583

Insert Customer No.

or ☐ Correspondence address below

NAME					
ADDRESS					
CITY			STATE	ZIP CODE	
COUNTRY			TELEPHONE	FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

NY2: 1464565.1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Prior application: Examiner James M. SpearArt Unit 1615

Commissioner for Patents  
P.O. Box 1450  
Mail Stop PATENT APPLICATION  
Alexandria, VA 22313-1450

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of Application No. 09/777,616, filed on February 6, 2001; which is a continuation of Application No. 09/360,056, filed on July 23, 1999, now Patent No. 6,261,599; which is a continuation of Application No. 08/833,948, filed on April 10, 1997, now Patent No. 5,958,452; which is a continuation-in-part of Application No. PCT/US95/14745, filed on March 11, 1995, which is a continuation-in-part of Application No. 08/334,209, filed on November 4, 1994, now Patent No. 5,965,161, the disclosure of each of which is incorporated by reference herein in its entirety

of Benjamin Oshlack, Mark Chasin, Hua-Pin Huang, David Sackler

(inventor(s) currently of record in prior application)

for MELT-EXTRUDED ORALLY ADMINISTABLE OPIOID FORMULATIONS

(title of invention)

1. ☒ The filing fee is calculated below:

**PATENT APPLICATION FEE VALUE**

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	24	- 20	4	\$18.00 each	\$ 72.00
Independent	3	- 3	0	\$84.00 each	\$ 0.00
Minimum Fee					\$ 750.00
Multiple Dependency Fee If Applicable (\$280.00)					\$ 0.00
<b>Total</b>					\$ 822.00
Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					\$ 0.00
<b>Total Filing Fee</b>					\$ 822.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☒ Please amend the specification in accordance with the Preliminary Amendment submitted herewith by inserting before the first line the following sentence: This application is a continuation of Application No. 09/777,616, filed on February 6, 2001; which is a continuation of Application No. 09/360,056, filed on July 23, 1999, now Patent No. 6,261,599; which is a continuation of Application No. 08/833,948, filed on April 10, 1997, now Patent No.

5,958,452; which is a continuation-in-part of Application No. PCT/US95/14745, filed on March 11, 1995, which is a continuation-in-part of Application No. 08/334,209, filed on November 4, 1994, now Patent No. 5,965,161, the disclosure of each of which is incorporated by reference herein in its entirety.

- 4a. ☐ New formal drawings are enclosed.
- 4b. ☐ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. \_\_\_\_\_ filed on \_\_\_\_\_ is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. \_\_\_\_\_, filed \_\_\_\_\_.
6. ☒ The prior application is assigned of record to **Euro-Celtique S.A.** \_\_\_\_\_.
- 7a. ☐ A copy of the Power of Attorney filed in the prior application no. \_\_\_\_\_, filed \_\_\_\_\_ is enclosed.
- 7b. ☐ A Power of Attorney is enclosed.
8. ☐ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no., filed on \_\_\_\_\_ be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. \_\_\_\_\_ is enclosed.
9. ☐ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. \_\_\_\_\_ is the same as the content of the computer readable form submitted in application no. \_\_\_\_\_.
10. ☐ DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
11. ☐ Additional enclosures or instruction \_\_\_\_\_

Date September 16, 2003

Respectfully submitted,

*Gidon D. Stern* Reg. No.: 27,469  
*by Brian C. Remy* Reg. No.: 48,176, 27,469  
Gidon D. Stern (Reg. No.)  
PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711